Pharmacogenomics & SNPs to Headline New Genomic Technologies Conference & Exposition in Princeton, NJ, July 16-18, 2001

Apr 20, 2001, 01:00 ET from Strategic Research Institute

    PRINCETON, N.J., April 20 /PRNewswire/ -- Late-breaking advances in
 genomic research in the related fields of pharmacogenomics, SNP's, target
 identification & validation, microarrays, and bioinformatics will be the focus
 of a comprehensive new meeting entitled "New Genomic Technologies Accelerating
 Drug Discovery," to take place in Princeton, NJ on July 16-18, 2001, announces
 Strategic Research Institute.
     The meeting, divided into five discrete sections are as follow: 1) target
 identification & validation, 2) pharmacogenomics & SNP's, 3) expression
 profiling & microarrays, 4) proteomics, and 5) bioinformatics, will feature
 prominent pharmaceutical and biotech scientists revealing their newest
 findings.
     Presenting papers on pharmacogenomics & SNPs will be Celera Genomics,
 Affymetrix, Orchid Biosciences, The SNP Consortium, and NeoGenesis, all of
 whom are paving the way for the development of genomics-based therapeutics.
     Other presentations on behalf of the industry will be Millenniu
 Pharmaceuticals, Human Genome Sciences, Hoffmann-La Roche, Merck,
 GlaxoSmithKline, Schering-Plough, Bristol-Myers Squibb, DuPont
 Pharmaceuticals, Affymetrix, Wyeth-Ayerst, CuraGen, Incyte Genomics, Myriad
 Genetics, Ciphergen Biosystems, Nanogen, Rosetta Inpharmatics, Genomics
 Research Institute of the Novartis Foundation, Genaissance Pharmaceuticals,
 Genometrix, AxCell Biosciences, Exelixis, Cellomics, and Galapagos Genomics.
     To receive the full agenda and/or register for the conference, please
 contact Jon E. Liong of Strategic Research Institute at jliong@srinstitute.com
 or 212-967-0095, x243 (please include name, corporate affiliation, mailing
 address, and fax number).
     To register as an exhibitor or to sponsor a function, please contact Mark
 Alexay at malexay@srinstitute.com.
 
 

SOURCE Strategic Research Institute
    PRINCETON, N.J., April 20 /PRNewswire/ -- Late-breaking advances in
 genomic research in the related fields of pharmacogenomics, SNP's, target
 identification & validation, microarrays, and bioinformatics will be the focus
 of a comprehensive new meeting entitled "New Genomic Technologies Accelerating
 Drug Discovery," to take place in Princeton, NJ on July 16-18, 2001, announces
 Strategic Research Institute.
     The meeting, divided into five discrete sections are as follow: 1) target
 identification & validation, 2) pharmacogenomics & SNP's, 3) expression
 profiling & microarrays, 4) proteomics, and 5) bioinformatics, will feature
 prominent pharmaceutical and biotech scientists revealing their newest
 findings.
     Presenting papers on pharmacogenomics & SNPs will be Celera Genomics,
 Affymetrix, Orchid Biosciences, The SNP Consortium, and NeoGenesis, all of
 whom are paving the way for the development of genomics-based therapeutics.
     Other presentations on behalf of the industry will be Millenniu
 Pharmaceuticals, Human Genome Sciences, Hoffmann-La Roche, Merck,
 GlaxoSmithKline, Schering-Plough, Bristol-Myers Squibb, DuPont
 Pharmaceuticals, Affymetrix, Wyeth-Ayerst, CuraGen, Incyte Genomics, Myriad
 Genetics, Ciphergen Biosystems, Nanogen, Rosetta Inpharmatics, Genomics
 Research Institute of the Novartis Foundation, Genaissance Pharmaceuticals,
 Genometrix, AxCell Biosciences, Exelixis, Cellomics, and Galapagos Genomics.
     To receive the full agenda and/or register for the conference, please
 contact Jon E. Liong of Strategic Research Institute at jliong@srinstitute.com
 or 212-967-0095, x243 (please include name, corporate affiliation, mailing
 address, and fax number).
     To register as an exhibitor or to sponsor a function, please contact Mark
 Alexay at malexay@srinstitute.com.
 
 SOURCE  Strategic Research Institute